The Oncology Institute, Inc. (NASDAQ:TOI) Major Shareholder Richy Agajanian Sells 1,600,000 Shares

The Oncology Institute, Inc. (NASDAQ:TOIGet Rating) major shareholder Richy Agajanian sold 1,600,000 shares of the business’s stock in a transaction on Wednesday, May 11th. The shares were sold at an average price of $6.00, for a total transaction of $9,600,000.00. Following the sale, the insider now owns 253,436 shares of the company’s stock, valued at $1,520,616. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

NASDAQ:TOI opened at $6.12 on Friday. The Oncology Institute, Inc. has a one year low of $3.75 and a one year high of $12.66. The business has a fifty day moving average of $7.15.

Oncology Institute (NASDAQ:TOIGet Rating) last posted its quarterly earnings data on Thursday, March 10th. The company reported $0.26 EPS for the quarter. The company had revenue of $52.30 million during the quarter.

Several large investors have recently bought and sold shares of TOI. Deerfield Management Company L.P. Series C bought a new position in Oncology Institute in the 4th quarter worth $32,137,000. Redmile Group LLC bought a new position in Oncology Institute in the 4th quarter worth $24,375,000. Vanguard Group Inc. boosted its holdings in Oncology Institute by 89.5% in the 1st quarter. Vanguard Group Inc. now owns 838,321 shares of the company’s stock worth $5,977,000 after buying an additional 395,977 shares during the period. Parian Global Management LP bought a new position in Oncology Institute in the 4th quarter worth $4,550,000. Finally, Triatomic Management LP boosted its holdings in Oncology Institute by 7.0% in the 1st quarter. Triatomic Management LP now owns 428,100 shares of the company’s stock worth $3,052,000 after buying an additional 28,100 shares during the period.

Oncology Institute Company Profile (Get Rating)

The Oncology Institute, Inc, an oncology company, provides medical oncology services in the United States. Its services include physician services, in-house infusion and dispensary, clinical trial services, radiation, outpatient stem cell transplants and transfusions programs, and patient support. The company also offers and manages clinical trial services, such as managing clinical trials, palliative care programs, and stem cell transplants services.

Further Reading

Receive News & Ratings for Oncology Institute Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncology Institute and related companies with MarketBeat.com's FREE daily email newsletter.